The mechanism of constitutive activation of KIT is explained in >90% of patients with SM by the existence of somatic activating point mutations located at exon 17 of KIT, where resides the catalytic domain of the receptor (Kristensen et al., 2014; Jara-Acevedo et al., 2015). Here, KIT is linked to systemic mastocytosis.